MedTrace Logo

Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature

NCT06740656 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2025-02-18

No results posted yet for this study

Summary

MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.

With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.

Yet, so far, these complications have only been documented in a few single case reports.

Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.

Conditions

  • Myositis
  • Myasthaenia Gravis
  • Neuropathy
  • Guillain Barré Syndrome
  • Parsonage Turner Syndrome

Interventions

OTHER

No Interventions

no intervention

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Pauline Ducatel, Doctor · CHRU Nancy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06740656 on ClinicalTrials.gov